• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    AJO International

    AJO International

    JournalISSN 2950-2535eISSN 2950-2535

    年发文量

    研究主题

    论文(322)

    排序
    1Brepocitinib in Patients with Active Noninfectious Uveitis: Results from the Phase 2 NEPTUNE Trial
    Quan Dong Nguyen,Mark Dacey,Robert Wang,Dilraj S. Grewal, Kelly L. Larkin,Edmund Tsui,Akshay Thomas,Christopher R. Henry,David S. Chu, Steven Yeh,Stephen Anesi, James T. Walsh,

    Objective To evaluate the efficacy and safety of brepocitinib, an oral, selective tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, in adults with active NIU. Design NEPTUNE was a 52-week, phase 2, multicenter, double-masked, randomized, dose-ranging clinical trial conducted in the United States between November 2022 and July 2024. Participants were randomized 2:1 to receive brepocitinib 45 mg or 15 mg once daily. All participants underwent an accelerated protocol-mandated glucocorticoid taper, with discontinuation of systemic and topical steroids by Week 8. Subjects Adults between the ages of 18 and 74 with active NIU were eligible for enrollment. Intervention and methods Participants received oral brepocitinib 45 mg or 15 mg once daily. The primary efficacy outcome was the proportion of participants experiencing treatment failure (TF) by Week 24, which was compared with a prespecified historical placebo rate of 80%. Additional outcomes included TF through Week 52 and effects on visual acuity, ocular inflammation, and macular edema. Safety was assessed in all participants who received at least one dose of brepocitinib. Results Twenty-six participants (mean age, 42 years; 65% female) were enrolled. By Week 24, TF occurred in 29.4% (95% CI, 10.3–56.0) of participants receiving brepocitinib 45 mg and 44.4% (95% CI, 13.7–78.8) receiving brepocitinib 15 mg, reflecting significant reductions relative to the prespecified historical placebo rate (p < 0.0001 and p = 0.0196, respectively). Through Week 52, only one additional TF event occurred in each treatment group. Improvements in visual acuity, posterior segment inflammation, and macular edema favored brepocitinib 45 mg. Brepocitinib was generally well-tolerated, with no deaths, major adverse cardiovascular events, venous thromboembolic events, or malignancies. Conclusions In this phase 2 randomized trial, brepocitinib was associated with low TF rates and rapid, durable disease control despite an accelerated glucocorticoid taper. Improvements across clinical, angiographic, and structural outcomes favored the 45 mg dose and support further evaluation of TYK2/JAK1 inhibition as a promising glucocorticoid-sparing treatment strategy for NIU.Trial registration ClinicalTrials.gov, NCT05523765

    2026
    引用
    AI阅读
    加入学术空间
    2Diagnostic Capacity of Melbourne Rapid Fields Online Perimetry 24–2 Rapid Protocol for Glaucoma Detection
    Kae Sugihara,George Yu Xiang Kong, Algis J. Vingrys, Mitsuto Hosokawa,Toshio Okanouchi

    Purpose To evaluate the diagnostic capacity of Melbourne Rapid Fields 24–2 Rapid protocol (MRFr) web–browser perimetry using clinical examination, Humphrey Visual Field Analyzer Swedish Interactive Thresholding Algorithm Standard (HFA–SS), and optical coherence tomography as the reference standards. Design Prospective cross–sectional study. Subjects Eighty–three eyes from 83 glaucoma patients and 52 eyes from 52 non–glaucoma participants were enrolled at Kurashiki Medical Center. Methods Participants underwent HFA–SS 24–2, followed by MRFr. The primary outcome measures included mean deviation (MD), pattern standard deviation (PSD), test false–positive rate, and test duration. Results MRFr returned a significant level of agreement with HFA–SS for MD (Intraclass Correlation Coefficient, ICC = 0.91 {95% Confidence Limit, CL 0.87 to 0.94}) and PSD (ICC = 0.89 {95%CL 0.82 to 0.93}). Bland–Altman analysis for MRFr and HFA–SS found a bias of –0.70 decibels (dB) (Coefficient of Repeatability, CoR = 6.74) for MD and +0.77 dB (CoR = 5.17) for PSD. To evaluate the performance of HFA–SS and MRFr for diagnosing glaucoma, receiver operating characteristic (ROC) curves were analyzed. Although a statistically significant difference in sensitivity of MD was observed at a specificity of 95% (51.8% for HFA–SS, 68.7% for MRFr; p = 0.009), the overall difference in the area under the curve (AUC) of the ROC curves was small, and the ROC curves crossed at certain points. The AUCs for MD were 0.87 ± 0.03 and 0.85 ± 0.03 for MRFr and HFA–SS, respectively. AUCs for PSD were 0.85 ± 0.03 and 0.91 ± 0.03 for MRFr and HFA–SS, respectively. The average test false–positive rate of MRFr was lower than that of HFA–SS (2.0 ± 4.6 vs 2.8 ± 4.0; p = 0.006). MRFr (161 ± 41 s) was significantly faster than HFA–SS (329 ± 67 s) (p < 0.001). Conclusion MRFr provides fast, portable, reliable visual field test for glaucoma diagnosis.

    2026
    引用
    AI阅读
    加入学术空间
    3Conjunctival Fornix Reconstruction with Commercially Available COMET Sheet after Failed Previous AMT: A Case Series
    Seitaro Komai, Yuto Kataoka,Koji Kitazawa,Hideki Fukuoka,Chie Sotozono

    Purpose: To report the surgical outcomes and clinical course after cultivated autologous oral mucosal epithelial transplantation (COMET) using Sakracy® (CynosBio, Inc.), a commercially available autologous oral mucosal epithelial cell sheet cultured on human amniotic membrane (AM) for conjunctival fornix reconstruction in eyes with severe ocular surface disorders after previous AM transplantation (AMT). Observations: This retrospective interventional case series study involved 3 eyes of 3 patients (1 male and 2 females) with severe cicatricial ocular surface disorders; i.e., 2 eyes with clinically diagnosed ocular cicatricial pemphigoid and 1 eye with Stevens–Johnson syndrome. All 3 eyes had previously undergone AMT, after which recurrent symblepharon and/or progressive fornix shortening developed. Symblepharon release and COMET using Sakracy® were subsequently performed for conjunctival fornix reconstruction. In all cases, a deep conjunctival fornix was maintained throughout the 20- to 29-month follow-up, allowing continued therapeutic limbal-rigid contact lens (Suncon Kyoto-CS; Sun Contact Lens Co., Ltd.) wear in 2 eyes. However, 1 eye required additional AMT for partial symblepharon recurrence, and persistent ocular surface keratinization remained in another eye. Conclusion: The findings in this case series suggest that COMET using Sakracy® may represent a useful therapeutic option to maintain a deep conjunctival fornix in eyes with severe cicatricial ocular surface disorders when previous AMT insufficiently maintains fornix reconstruction.

    2026
    引用
    AI阅读
    加入学术空间
    4Evaluating Global Glaucoma Awareness Efforts: A Study of World Glaucoma Week Activities and Influencing Factors
    Kasem Seresirikachorn, Nattaporn Vongsa, Ta Chen Peter Chang

    Purpose To assess the global distribution of awareness and screening activities conducted during World Glaucoma Week (WGW) and to identify national-level factors associated with activity frequency. Design Cross-sectional observational study. Subjects Countries and cities reporting WGW activities (2015–2024) on the official WGW website. Methods Activity rates were standardized per 10,000 individuals with glaucoma-related blindness in each country. Pearson’s and Spearman’s correlation analysis was used to examine associations between WGW activity levels and national indicators, including the presence of a glaucoma society, the number of ophthalmologists, Gross Domestic Product (GDP), and Inequality-adjusted Human Development Index (IHDI) Results An average of 548.1 WGW activities were reported annually. Public education (30.9%) and awareness campaigns (30.2%) were the most frequently conducted activities. Manila, Philippines, reported the highest average number of activities per year (35.3), followed by Quito, Ecuador, and Bogotá, Colombia. When adjusted for glaucoma-related blindness, Antigua and Barbuda had the most frequent activities, followed by Barbados and Croatia. Countries with a national glaucoma society reported significantly more activities (median 19.50 [IQR 4.00–54.75] vs. 0.00 [IQR 0.00–2.50]; p < 0.001). Significant correlations were observed between WGW activity levels and population size, IHDI, number of ophthalmologists, and glaucoma blindness prevalence as estimated by the Global Burden of Disease Study. Conclusions Marked global disparities exist in glaucoma awareness efforts. The presence of a national glaucoma society is strongly associated with increased WGW activity levels, underscoring the critical role of organized professional support as a major driver of glaucoma awareness worldwide.

    2026
    引用
    AI阅读
    加入学术空间
    5Vitreous Water Dynamics and the Hydration-Floater Myth: A Critical Appraisal of Barrier Physiology, Floater Pathophysiology, and Clinical Implications of Misattributing Symptoms to Dehydration
    Pierpaolo Emanuele Maimone

    Topic The claim that increasing oral water intake reduces vitreous floaters or restores vitreous integrity is widespread across social media and clinical settings. This narrative review evaluates the biological plausibility of this claim using established vitreous physiology, barrier transport data, floater pathophysiology, and an original quantitative appraisal. A clearly delineated hypothesis regarding seasonal variation in posterior vitreous detachment is also presented. Clinical relevance New or worsening floaters may signal retinal tear, rhegmatogenous retinal detachment, vitreous hemorrhage, endophthalmitis, posterior uveitis, primary vitreoretinal lymphoma, or proliferative diabetic retinopathy. With ophthalmology-related content accumulating billions of views on social media platforms and a substantial proportion containing inaccurate information, the hydration-floater claim has the potential to delay diagnosis of sight-threatening or life-threatening conditions. Methods Narrative critical review of primary literature on vitreous physiology, blood-retinal barrier kinetics, aquaporin-mediated water transport, collagen type II biology, hyaluronic acid biochemistry, vitreous ascorbate physiology, floater pathophysiology, and the epidemiology of seasonal posterior vitreous detachment. Literature searched in PubMed, Scopus, and Embase through June 2026. Original quantitative calculations are explicitly labeled as author-derived estimates throughout. This review does not constitute a systematic review or meta-analysis. Results Vitreous water content (∼4.14 mL per eye; 0.02% of total body water) is maintained by the blood-retinal barrier and aquaporin-4-mediated Müller cell transport, largely independently of oral intake. Author-derived quantitative estimates indicate that the theoretical water influx from systemic oral loading is approximately 1.2% of vitreous volume per eye (0.049 mL / 4.14 mL) under the maximally favorable scenario of completely unrestricted equilibration with no barrier restriction — and substantially less under realistic physiological conditions. Floaters arise from thermodynamically highly favored aggregation of collagen type II fibrils following hyaluronic acid depletion — a process that is effectively irreversible under physiological conditions given the activation energies involved (15–50 kJ/mol); the vitreous becomes progressively more liquid with aging, not less. The largest epidemiological study on water intake and ocular surface disease (n=51,551) found no protective effect against dry eye disease. Increased oral hydration has not been demonstrated to reduce floaters in any published study. As a hypothesis-generating proposal, seasonal variation in posterior vitreous detachment and rhegmatogenous retinal detachment in temperate climates may reflect thermodynamic destabilization of vitreous collagen near its melting transition temperature, rather than dehydration; this mechanism awaits direct experimental validation. Conclusions Increased oral water intake has not been demonstrated to alter vitreous water content, collagen fibril architecture, or floater burden. These processes are regulated by the blood-retinal barrier and membrane transport mechanisms in a manner largely independent of systemic hydration, though direct in vivo measurement under graded oral loading conditions in humans remains an evidence gap. New or worsening floaters require ophthalmological evaluation, not reassurance based on hydration advice.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 322 篇论文

    高被引作者

    作者引用发文
    Stanislao Rizzo78
    Subhi Yousif615
    Klefter Oliver Niels58
    Constance Weber53
    Jakob Grauslund512
    Alfonso Savastano43
    Federico Giannuzzi46
    Michael Balas46
    Benjamin J. Kim32
    Klein Ainat31

    高产作者

    作者引用发文
    Subhi Yousif615
    Jakob Grauslund512
    Popovic Marko210
    Stephanie Watson28
    Klefter Oliver Niels58
    Stanislao Rizzo78
    Ryan Huang17
    Himal Kandel16
    Hashem Abu Serhan16
    Michael Balas46

    相关期刊

    暂无数据
    暂无数据